AHSR 2020 Virtual’s Main Event had nationally renowned speakers share the latest, cutting-edge research. Read the bios below to learn more about the speakers!
Topic: Publishing in Addiction Health Services Research
Lewei Allison Lin
Lewei Allison Lin, MD, is an addiction psychiatrist and Assistant Professor in the Department of Psychiatry as well as research investigator at the VA Center for Clinical Management Research. She investigates ways to improve treatment for patients with opioid and other substance use disorders and uses large electronic health datasets to better understand medical, mental health and other correlates for patients with substance use disorders. Dr. Lin is interested in developing telehealth interventions to improve access to evidence based treatments for substance use disorders and to better understand disparities in treatment.
Kelly Dunn, PhD, MBA, is an Associate Professor within the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine, Co-Editor at the Journal of Addiction Medicine, and an active clinical researcher. She conducts NIDA-funded research that examines mechanisms of opioid use disorder using human laboratory studies as well as potential intervention targets to improve opioid withdrawal symptom management and treatments for comorbid pain. In addition to her work at the Journal of Addiction Medicine, she is on the Board of Directors and the Chair of the program committee for the College on the Problems of Drug Dependence, on the Board of Convention Affairs for the American Psychological Association, and is President-Elect of APA Division 28 (Psychopharmacology and Substance Abuse).
Topic: NIAAA and NIDA Priorities for Addiction Health Services Research
Laura Kwako, PhD, is a clinical psychologist and program officer in the Division of Treatment and Recovery Research at NIAAA. Her research portfolio focuses on health services, including treatment availability, quality and use, along with health care systems and integration of various health care services. Dr. Kwako received her PhD. in Clinical Psychology from the Catholic University of America and completed postdoctoral clinical training at Springfield Hospital Center in Maryland, specializing in treatment for addiction and trauma-related disorder in an inpatient, primarily forensic, setting. Dr. Kwako is licensed in Washington, DC and credentialed at the NIH Clinical Research Center as a clinical psychologist.
Tisha Wiley, PhD, is the Chief of the Services Research Branch (SRB) and Associate Director for Criminal Justice at the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). Dr. Wiley currently leads the Justice Community Opioid Innovation Network (JCOIN), a 5-year $150M initiative focused on transforming responses to the opioid crisis in the justice system. As the Chief of the Services Research Branch, Dr. Wiley leads a team responsible for managing a diverse portfolio of > 350 grants focused on addiction health services research, totaling over $335M annually. Prior to joining NIH, she was the Assistant Director of Research at the Juvenile Protective Association, a non-profit social service agency in Chicago.
Topic: Accelerating the Research to Practice Pipeline via Hybrid Trials in Addiction Health Services Research
Geoffrey Curran, PhD, is a medical sociologist and a Professor of Pharmacy Practice and Psychiatry at the University of Arkansas for Medical Sciences (UAMS). His broad research area has been health services research, with focus areas in 1) predictors of treatment engagement and outcomes for mental health and substance use disorders, and 2) diffusion of innovation in a variety of health care settings (e.g., pharmacy, specialty care, primary care, and community settings). He is the Director of the Center for Implementation Research, which is supported by the Translational Research Institute (TRI, UL1 TR003107), through the National Center for Advancing Translational Sciences of the National Institute of Health (NIH). The Center is devoted to developing and testing implementation strategies across a wide range of service contexts, assisting with the implementation of practices within community practices, and training the next generation of implementation scientists.
Hildi Hagedorn (Hybrid 1)
Dr. Hildi Hagedorn, PhD, is a Principal Investigator and Director of the Implementation Science Core in the Center for Care Delivery and Outcomes Research at the Minneapolis VA Medical Center. She is an associate professor in the Department of Psychiatry at the University of Minnesota School of Medicine. Her main area of research interest is implementation of evidence-based treatments for substance use disorders with a focus on medication treatments for alcohol and opioid use disorders and integration of substance use disorders treatment into primary care settings.
Bryan Garner (Hybrid 2)
Bryan Garner, PhD, is a Senior Implementation Research Scientist with RTI International. Dr. Garner received his PhD in Experimental Psychology from Texas Christian University in 2006. His program of research focuses on improving the implementation of evidence-based treatments for substance use disorders. Regarding hybrid trials, Dr. Garner has experience conducting Type 1, Type 2, and Type 3 hybrid trials.
Mark McGovern (Hybrid 3)
Mark McGovern, PhD, is a Professor in the Department of Psychiatry and Behavioral Sciences, and in the Department of Medicine at Stanford University School of Medicine. He is the Co-Chief of the Division of Public Mental Health and Population Sciences (Psychiatry) and Medical Director of Integrated Behavioral Health in the Division of Primary Care and Population Health (Medicine). He is Core Faculty at the NIH implementation Research Institute where he mentors NIDA Fellows, and a standing member of the NIDA study section on Interventions for the Prevention and Treatment of Addiction.
Ana Baumann, PhD, is the co-director of the Dissemination and Implementation Research Core (DIRC), an Institute of Clinical and Translational Sciences (ICTS) Core that provides methodological expertise to advance translational research and move efficacious health practices from clinical knowledge to routine care. Her research agenda focuses on identifying strategies to facilitate the dissemination and implementation of evidence-based interventions in low-resource settings nationally and globally. Through DIRC, she has supported multiple investigators as an implementation scientist and helped them to receive federal funding to conduct studies aiming to accelerate the use of evidence-based interventions or guidelines in different settings of care.
Topic: Point/Counterpoint: It’s Time to X the Waiver vs. Patients with Opioid Use Disorder Deserve Trained Providers
H. Westley Clark
H. Westley Clark, MD, MPH, JD, is Dean’s Executive Professor of Public Health at Santa Clara University, as well as a psychiatrist, lawyer, and expert on substance use treatment, pain management, and psychopharmacology. As director of the Center for Substance Abuse Treatment at the Substance Abuse and Mental Health Services Administration from 1998 to 2014, Clark led the nation’s effort to make evidence-based addiction treatment more accessible to Americans. He has been the recipient of multiple awards for his service and scholarship including the 2015 Lisa Mojer-Torres Award from Faces & Voices of Recovery, the 2015 James Ralph Memorial Award for Outstanding Public Service from the Black Psychiatrists of America, the 2015 Annual Award from the American Society of Addiction Medicine, and the 2008 John P. McGovern Award from the American Society of Addiction Medicine.
Sarah E. Wakeman, MD, is an Addiction Medicine Physician who serves as Medical Director for the Mass General Hospital Substance Use Disorder Initiative, program director of the Mass General Addiction Medicine fellowship, Medical Director of the Mass General Hospital Addiction Consult Team, co-chair of the Mass General Opioid Task Force, clinical co-lead of the Partners Healthcare Substance Use Disorder Initiative, and co-chair of the Partners Healthcare Opioid Steering Committee. She is an Associate Professor of Medicine at Harvard Medical School. She is also the chief Medical Officer of RIZE Massachusetts.
David A. Fiellin, MD, is a Professor of Medicine, Emergency Medicine and Public Health at Yale where he directs the Yale Program in Addiction Medicine. He is an internist and board certified in Addiction Medicine. He directed DATA 2000 training for the American Society of Addiction Medicine for 5 years and served as the first medical director of the Physician Clinical Support System (PCSS). He was Co-Editor of the ASAM textbook, Principles of Addiction Medicine, 4th, 5th, and 6th Editions
Topic: Developing an Anti-Racist Recovery Movement in Practice and Research
Ayana Jordan MD/PhD, MS, is an associate program director of the psychiatry residency program at Yale University, an assistant professor of psychiatry, and an attending physician at Connecticut Medical Center. She is committed to increasing access to addiction services within minority communities, both nationally and abroad. Dr. Jordan was recently appointed the new director of the Yale Psychiatry Residency Global Mental Health Program. Dr Jordan is the proud recipient of multiple clinical and research awards for her contribution to the field, including being inducted into the Top 40 under 40 society, by her undergraduate alma mater.